bit.bio, an award-winning human synthetic biology company with a mission to code cells for novel cures, has secured $50.0 million in new funding. This significant investment round will support the company's ongoing development and expansion of its proprietary cell programming platform, which aims to revolutionize drug discovery and cell therapy.
The company has developed an end-to-end platform for the creation of any human cell type. Central to this is its cutting-edge and patent-protected opti-ox precision cell programming technology. This innovation allows bit.bio to deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, approximately 10 times faster than conventional methods. This platform holds the potential to unlock a new generation of medicines.
bit.bio's io Cells research products currently provide scientists with highly characterised, consistent, and scalable human cells, enabling research and drug discovery teams to accelerate experimental timelines and reduce variability. The company is also leveraging its platform to build a pipeline of txCells for cell therapies. This capital infusion is expected to be deployed towards scaling these operations, further developing the opti-ox platform, and advancing its therapeutic pipeline.
The funding underscores investor confidence in bit.bio's innovative approach to synthetic biology and its potential impact on medical research and treatment. With this investment, bit.bio is positioned to accelerate its research and development efforts, strengthen its team of pioneers in stem cell biology and cell programming, and broaden the reach of its advanced cellular solutions. The company aims to continue its trajectory of growth, bringing its technology to a wider range of scientific and therapeutic applications.
